By: IPP Bureau
Last updated : October 09, 2026 10:13 am
The business continues to see very strong demand for the RUBY-FILL
Jubilant Draximage Inc. is investing CAD 94.5 million to modernize and expand its facility in Kirkland, Québec. The expansion will boost the production capacity of its radiopharmaceutical pipeline and double the output of its flagship product, RUBY-FILL.
The company is a subsidiary of Jubilant Pharma Limited, which is wholly owned by Jubilant Pharmova. To support the project, the Government of Canada is contributing CAD 23.8 million in financial aid.
The business continues to see very strong demand for the RUBY-FILL, the customer base has doubled in the last 3 years. This expansion will allow Jubilant to fulfil the elevated demand.
Speaking on the announcement, Harsher Singh, CEO, Jubilant Radiopharma business said, "This investment recognizes Jubilant Radiopharma's innovation capabilities in Nuclear Medicine and the important role our sector plays in advancing both diagnostic and therapeutic treatments. This project will build our deep capability here in Quebec, create and secure high-value jobs, and ensure a reliable supply of essential radiopharmaceutical products in Canada and around the world. "
Jubilant Radiopharma provides diagnostic and therapeutic nuclear medicine solutions across oncology, cardiology, and neurology. Its portfolio features RUBY-FILL for Rubidium-82 production in cardiac PET imaging, Technetium-99m for a variety of diagnostic SPECT procedures, and Iodine-131 for the targeted radiation treatment of thyroid diseases and neuroblastoma.
The Kirkland facility is the only site in Canada producing these product categories. The investment will support the modernization and expansion of the facility, including the installation of state-of-the-art production equipment, enabling Jubilant Radiopharma to double its manufacturing capacity to meet growing global demand for RUBY- FILL.